Table 3.
Longitudinal associations between treatment-related factors and memory symptoms in 330 cancer survivors with different cancer diagnoses
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |
|---|---|---|---|---|---|
| Intercept | 32.10 (29.97, 34.22)*** | 31.38 (27.85, 34.90)*** | 30.33 (17.39, 43.27)*** | 31.98 (17.71, 46.24)*** | 24.99 (10.80, 39.17)*** |
| Time | |||||
| Baseline | Ref | Ref | Ref | Ref | Ref |
| 6 months | − 1.00 (− 2.54, 0.55) | − 1.08 (− 2.65, 0.49) | − 1.08 (− 2.66, 0.50) | − 1.00 (− 2.61, 0.60) | − 0.19 (− 1.81, 1.44) |
| 12 months | − 0.75 (− 2.27, 0.77) | − 0.68 (− 2.22, 0.85) | − 0.69 (− 2.23, 0.86) | −0. 56 (− 2.14, 1.02) | 0.07 (− 1.52, 1.66) |
| 18 months | − 1.60 (− 3.29, 0.09) | − 1.49 (− 3.25, 0.27) | − 1.51 (− 3.27, 0.26) | − 1.55 (− 3.33, 0.24) | − 1.08 (− 2.85, 0.68) |
| Type of cancer treatment | |||||
| Locoregional treatment | Ref | Ref | Ref | Ref | |
| Chemotherapy | 0.09 (− 4.23, 4.40) | − 1.77 (− 6.19, 2.65) | − 2.81 (− 7.80, 2.19) | − 2.30 (− 7.11, 2.50) | |
| Other systemic therapy1 | 8.37 (0.94, 15.79)* | 8.30 (1.21, 15.40)* | 11.55 (3.32, 19.78)** | 11.14 (3.06, 19.21)** | |
| Gender | |||||
| Male | Ref | Ref | Ref | ||
| Female | 5.27 (1.10. 9.45)* | 4.53 (− 0.35, 9.42) | 4.69 (0.00, 9.38) | ||
| Age | − 0.05 (− 0.28, 0.19) | − 0.08 (− 0.31, 0.16) | − 0.04 (− 0.27. 0.19) | ||
| Education | |||||
| High | Ref | Ref | Ref | ||
| Medium | 4.82 (0.23, 9.41)* | 4.62 (− 0.03, 9.28) | 4.47 (− 0.03, 8.97) | ||
| Low | − 1.52 (− 6.36, 3.32) | − 1.51 (− 6.39, 3.37) | − 1.43 (− 6.15, 3.30) | ||
| Treatment completed | |||||
| Yes | Ref | Ref | |||
| No | − 1.27 (− 6.13, 3.59) | − 1.39(− 6.11, 3.33) | |||
| Time diagnosis to RTWa | − 0.27 (− 0.58, 0.05) | − 0.23 (− 0.53, 0.08) | |||
| Extent of disease | |||||
| Local | Ref | Ref | |||
| Regional | − 0.72 (− 5.87, 4.43) | − 0.70 (− 5.66, 4.26) | |||
| Distant | − 5.10 (− 16.25, 6.04) | − 5.46 (− 16.02, 5.11) | |||
| Unknown | − 1.77 (− 7.14, 3.60) | − 2.01 (− 7.19, 3.17) | |||
| Depressive symptomsb | 0.11 (0.03, 0.20)** | ||||
| Fatiguec | 0.16 (0.06, 0.26)** | ||||
Note: *p value < 0.05; ** p value < 0.01; *** p value < 0.001. Intercept, slopes, and 95% confidence intervals were presented. 1Other “systemic” therapy using hormonal therapy or targeted therapy, exclusively or in combination with surgery and/or radiotherapy. RTW, return to work; a in months; b range 0–28 ; c range 8–56. Model 1 included n = 1126 (85.3%); Model 2 n = 1109 (84.0%); Model 3 n = 1102 (83.5%); Model 4 n = 1063 (80.5%); Model 5 n = 1063 (80.5%) of the 1320 possible person-measurement observations